KR101821925B1 - A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis - Google Patents
A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis Download PDFInfo
- Publication number
- KR101821925B1 KR101821925B1 KR1020170059864A KR20170059864A KR101821925B1 KR 101821925 B1 KR101821925 B1 KR 101821925B1 KR 1020170059864 A KR1020170059864 A KR 1020170059864A KR 20170059864 A KR20170059864 A KR 20170059864A KR 101821925 B1 KR101821925 B1 KR 101821925B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- broiler
- allergic dermatitis
- weight
- preventing
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 105
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 244000037364 Cinnamomum aromaticum Species 0.000 title claims description 3
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 title claims description 3
- 244000202052 Poncirus trifoliata Species 0.000 title claims description 3
- 235000000404 Poncirus trifoliata Nutrition 0.000 title claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 title description 3
- 208000026935 allergic disease Diseases 0.000 title description 3
- 230000007815 allergy Effects 0.000 title description 3
- 241000287828 Gallus gallus Species 0.000 claims abstract description 76
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 47
- 206010012434 Dermatitis allergic Diseases 0.000 claims abstract description 41
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 239000002537 cosmetic Substances 0.000 claims abstract description 18
- 230000036541 health Effects 0.000 claims abstract description 18
- 235000013376 functional food Nutrition 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 206010030113 Oedema Diseases 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 206010012442 Dermatitis contact Diseases 0.000 claims description 6
- 208000010247 contact dermatitis Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 3
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 235000004426 flaxseed Nutrition 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 5
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 abstract description 4
- 241000223218 Fusarium Species 0.000 abstract description 4
- 206010058679 Skin oedema Diseases 0.000 abstract description 2
- 230000002009 allergenic effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 22
- -1 stearide Substances 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000003814 drug Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000006071 cream Substances 0.000 description 11
- 210000003608 fece Anatomy 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 5
- 229960005205 prednisolone Drugs 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 240000006240 Linum usitatissimum Species 0.000 description 4
- 235000004431 Linum usitatissimum Nutrition 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 235000011511 Diospyros Nutrition 0.000 description 3
- 244000236655 Diospyros kaki Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 240000004371 Panax ginseng Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229940041476 lactose 100 mg Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002363 herbicidal effect Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 229940052490 naringin Drugs 0.000 description 2
- 229930019673 naringin Natural products 0.000 description 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- NLAWPKPYBMEWIR-SKYQDXIQSA-N (2S)-poncirin Chemical compound C1=CC(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 NLAWPKPYBMEWIR-SKYQDXIQSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241001105098 Angelica keiskei Species 0.000 description 1
- RSDDHGSKLOSQFK-PTNGSMBKSA-N Auraptene Natural products C1=CC(=O)OC2=CC(OC\C=C(C)/CCC=C(C)C)=CC=C21 RSDDHGSKLOSQFK-PTNGSMBKSA-N 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- 108091005960 Citrine Proteins 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- NLAWPKPYBMEWIR-VGQRFNKBSA-N Poncirin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C[C@@H](c3ccc(OC)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 NLAWPKPYBMEWIR-VGQRFNKBSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- SZKKRCSOSQAJDE-UHFFFAOYSA-N Schradan Chemical group CN(C)P(=O)(N(C)C)OP(=O)(N(C)C)N(C)C SZKKRCSOSQAJDE-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- PZQBWGFCGIRLBB-NJYHNNHUSA-N [(2r)-2-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1O PZQBWGFCGIRLBB-NJYHNNHUSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- RSDDHGSKLOSQFK-RVDMUPIBSA-N auraptene Chemical compound C1=CC(=O)OC2=CC(OC/C=C(C)/CCC=C(C)C)=CC=C21 RSDDHGSKLOSQFK-RVDMUPIBSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000019726 broiler meat Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 239000011035 citrine Substances 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000010512 hydrogenated peanut oil Substances 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- OLOOJGVNMBJLLR-UHFFFAOYSA-N imperatorin Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OCC=C(C)C OLOOJGVNMBJLLR-UHFFFAOYSA-N 0.000 description 1
- XKVWLLRDBHAWBL-UHFFFAOYSA-N imperatorin Natural products CC(=CCOc1c2OCCc2cc3C=CC(=O)Oc13)C XKVWLLRDBHAWBL-UHFFFAOYSA-N 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010204 pine bark Nutrition 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 지실 및 육계의 복합 추출물을 포함하는 알레르기성 피부염 예방 또는 치료용 약학적 조성물, 건강기능 식품 및 화장료 조성물에 관한 것이다. 본 발명의 지실 및 육계의 복합 추출물은 알레르기 원인 물질에 의해 유발된 피부 부종을 효과적으로 억제할 수 있으므로, 알레르기성 피부염을 예방 또는 치료하는 효과가 있다. The present invention relates to a pharmaceutical composition, a health functional food and a cosmetic composition for preventing or treating allergic dermatitis, which comprises a complex extract of fusarium and broiler chickens. The combined extracts of the flaxseed and broiler chicks of the present invention can effectively prevent skin edema induced by an allergenic substance, and thus have an effect of preventing or treating allergic dermatitis.
Description
본 발명은 지실 및 육계의 혼합 추출물을 포함하는 알레르기성 피부염 예방 또는 치료용 약학적 조성물, 건강기능 식품 및 화장료 조성물에 관한 것이다. The present invention relates to a pharmaceutical composition, a health functional food and a cosmetic composition for prevention or treatment of allergic dermatitis including a mixed extract of feces and broiler chickens.
산업 발달에 따른 환경오염이 가속화되면서 각종 면역과민성 질환을 유발하는 알레르겐이 급증하여, 알레르기성 질환인 기관지 천식, 비염, 알레르기성 결막염 및 피부염 등이 증가하고 있다. 알레르기는 주로 소화기, 중추신경계 및 피부에서 나타나며, 화학물질, 약물 및 기타 자극물질에 의해 유발될 수 있다. As the environmental pollution is accelerated due to the development of industry, allergens causing various immunological irritable diseases are rapidly increasing, and allergic diseases such as bronchial asthma, rhinitis, allergic conjunctivitis and dermatitis are increasing. Allergies mainly occur in the digestive system, central nervous system and skin, and can be caused by chemicals, drugs and other irritants.
알레르기성 피부염의 치료를 위하여 부신피질 호르몬제 및 항히스타민제가 사용되고 있으나 장기간 투여할 경우 여러 가지 부작용이 보고되고 있어 이에 대한 새로운 치료제의 개발이 필요한 실정이다. 특히 최근에는 화학약품이 아닌 천연 식물로부터 추출한 추출물을 이용하여 알레르기성 피부염을 치료하려는 연구가 활발히 이루어지고 있다. Although corticosteroids and antihistamines are used for the treatment of allergic dermatitis, various side effects have been reported when they are administered over a long period of time. In recent years, studies have been actively conducted to treat allergic dermatitis using extracts extracted from natural plants, rather than chemical agents.
지실은 운향과(Rutaceae)에 속한 상록소교목인 광귤나무 Citrus aurantium L. 탱자나무 Poncirus trifoliata Rafin.의 유과로, 5~6월에 미성숙 과실을 채취하여 가로로 쪼개어 두 쪽이 되게 한 다음 쇄건하거나 저온에서 건조한다. 한의학적으로 파기소적, 화담산비의 효능이 있으며 적체내정, 비만창통, 사리후중, 대변불통 등을 치료하는데 사용되어 왔다. Citrus aurantium L. tangerine, an evergreen tree belonging to the family Rutaceae, is an oily plant of Poncirus trifoliata Rafin. It picks up immature fruit from May to June, transversely divides it into two sides, Lt; / RTI > It has been used as a medicinal herb medicine, and it has been used for the treatment of rosacea, obesity, sari, insomnia and feces.
지실의 성분으로는 리모넨(limonene), 리나놀(linalool), 캄펜(camphene)등과 같은 정유성분, 폰키린(poncirin), 나린진(naringin), 헤스페리딘(hesperidin), 네오헤스페리딘(neohesperidin)등과 같은 프라보노이드 및 엄벨리페론(umbelliferone), 오랍텐(auraptene), 임페라토린(imperatorin)등과 같은 쿠마린류가 보고되어 있다. 폰키린은 항혈소판 작용 및 장내세균 억제작용과 항헬리코박터파이로리 활성이 있다고 알려져 있고, 나린진은 콜레스테롤 억제효과와 백혈병 세포를 정상세포로 변화시키는 작용, 유방암 세포증식 저해작용이 있는 것으로 보고되어 있다. 또한 지실의 물 추출물은 compound 48/80으로 유발한 아나필락시스 모델에서 복강 내 비만세포의 막(membrane)을 안정화시켜 아나필락시스 쇼크로 인한 쥐의 사망을 막는 효과가 있다고 보고된 바 있다. Examples of the follicle components include essential oils such as limonene, linalool, camphene and the like, pravastatin such as poncirin, naringin, hesperidin, neohesperidin, Coumarins have been reported, such as nodules and umbelliferone, auraptene, imperatorin, and the like. It has been reported that ponchirin has antitumor activity and intestinal bacterial inhibitory action and anti-helicobacter pylori activity, and Naringin has been reported to have cholesterol-inhibiting effect, leukemia cell to normal cell, and inhibition of breast cancer cell proliferation. In addition, water extracts of Fusarium wilt have been reported to stabilize the membranes of intraperitoneal mast cells in anaphylactic model induced by compound 48/80 and to prevent the death of rats due to anaphylactic shock.
육계(肉桂)는 녹나무과(Lauraceare)에 속한 상록교목인 육계 Cinnamommum cassia Presl의 수피로, 8~10월 사이에 채취하여 음건한다. 한의학적으로 보원양완비위, 제적냉, 통혈맥의 효능이 있으며 명문화쇠, 지냉맥미, 망양허탈, 복통설사, 한산분돈 등을 치료하는데 사용되어 왔다. Broiler meat is extracted from cinnamomum cassia Presl broth, which is an evergreen tree belonging to Lauraceare, between 8 and 10 months. It has been used as a medicinal medicine for the treatment of boiled pancreas, myrrh and cold blood vessels, and has been used for the treatment of stigmatism, gastrointestinal stomach,
육계에는 정유성분이 1~2% 함유되어 있는데, 주성분인 계피알데히드(cinnamaldehyde)가 75~90% 함유되어 있고, 이 외에 유제놀(eugenol), 탄닌(tannin) 성분이 함유되어 있다. 육계는 항생, 항균, 항바이러스, 항산화, 항암, 혈압 강하, 콜레스테롤 및 지질강하, 위-보호 등의 효능이 보고되어 있다.The broiler contains 1 ~ 2% of essential oil, which contains 75 ~ 90% of cinnamaldehyde as main ingredient and contains eugenol and tannin. Broilers have been reported to have antibiotic, antibacterial, antiviral, antioxidant, anticancer, hypotensive, cholesterol and lipid lowering, gastric-protective effects.
한국등록특허 제10-0981038호에는 지실 및 육계를 일부 구성요소로 포함하는 아토피 및 여드름 치료를 위한 조성물이 개시되어 있다. 상기 특허문헌에 따르면 지실 3~6 중량부, 백출 4~8 중량부, 숙지황 4~10 중량부, 천궁 4~8 중량부, 자초 5~12 중량부, 황금 4~9 중량부, 편백 6~10 중량부, 인진 8~15 중량부, 감초 4~9 중량부, 작약 4~9 중량부, 유근피 6~9 중량부, 우방자 5~9 중량부, 황련 2~3 중량부, 황백 3~9 중량부, 백선피 6~12 중량부, 어성초 6~15 중량부 및 시호 3~6 중량부를 포함하는 혼합 추출물은 아토피 및 여드름을 치료할 수 있으며, 상기 혼합물에 당귀 4~9 중량부, 복령 4~9 중량부, 황기 5~15 중량부, 육계 2~5 중량부, 건강 2~5 중량부, 단삼 5~15 중량부, 진피 3~9 중량부, 계지 3~9 중량부, 현삼 5~10 중량부, 금은화 6~15 중량부, 포공영 6~15 중량부 및 마치현 6~15 중량부를 추가적으로 혼합할 수 있음이 개시되어 있다. Korean Patent Registration No. 10-0981038 discloses a composition for treating atopy and acne, which comprises flax and broiler as a component. According to the patent document, 3 to 6 parts by weight of persimmon, 4 to 8 parts by weight of spearmint, 4 to 10 parts by weight of sorghum persimmon, 4 to 8 parts by weight of citrine, 5 to 12 parts by weight of fern, 4 to 9 parts by weight of gold, 10 to 10 parts by weight of starch, 8 to 15 parts by weight of starch, 4 to 9 parts by weight of licorice, 4 to 9 parts by weight of peony root, 6 to 9 parts by weight of rhizome root, 5 to 9 parts by weight of starchy rape, 2 to 3 parts by weight of rhizome, The mixture extract containing 6 to 12 parts by weight of pine bark, 6 to 15 parts by weight of bamboo shoot, and 3 to 6 parts by weight of bark can treat atopy and acne. To the mixture, 4 to 9 parts by weight of Angelica keiskei, 5 to 15 parts by weight of ginseng, 3 to 9 parts by weight of dandelion, 3 to 9 parts by weight of ginseng, 5 to 15 parts by weight of ginseng, 5 to 15 parts by weight of sulfur, 2 to 5 parts by weight of broth, 2 to 5 parts by weight of health, 6 to 15 parts by weight of gold, 6 to 15 parts by weight of phosphorus and 6 to 15 parts by weight of germanium can be further mixed.
그러나 상기 특허문헌의 복합 조성물은 지실 및 육계 외에도 27가지의 생약제의 추출물을 추가적으로 포함하고 있는 조성물로서 매우 많은 약제를 특정 비율로 혼합하는 경우에만 아토피 및 여드름을 치료할 수 있음이 개시되어 있고, 이중 일부 성분을 구성으로 하더라도 뛰어난 알레르기성 피부염 억제 반응을 나타낸다는 점에 대한 개시는 없다. However, the composite composition of the patent document additionally includes an extract of 27 genera herb medicine in addition to fecal and broiler, and it is disclosed that it is possible to treat atopy and acne only when a very large amount of medicines are mixed at a specific ratio, There is no disclosure that it exhibits an excellent allergic dermatitis suppressing reaction even when constituents are constituted.
본 발명자들은 알레르기성 피부염을 치료하기 위한 새로운 치료제 개발을 위하여 천연 생약제를 연구하던 중, 지실 및 육계 두 가지 생약제의 혼합 추출물이 뛰어난 알레르기성 피부염 억제반응을 나타내는 것을 확인하고 본 발명을 완성하였다. The inventors of the present invention confirmed that a mixed extract of two herbicidal and herbicidal herb extracts showed excellent allergic dermatitis suppression during the study of natural herb medicine for the development of a new therapeutic agent for treating allergic dermatitis.
따라서 본 발명의 목적은 지실 및 육계의 혼합 추출물을 포함하는 알레르기성 피부염 예방 또는 치료용 약학적 조성물을 제공하는 것이다. Accordingly, an object of the present invention is to provide a pharmaceutical composition for preventing or treating allergic dermatitis, which comprises a mixed extract of fowl and broiler chickens.
또한, 본 발명의 목적은 지실 및 육계의 혼합추출물을 포함하는 알레르기성 피부염 예방 또는 개선용 건강기능식품을 제공하는 것이다. It is also an object of the present invention to provide a health functional food for preventing or ameliorating allergic dermatitis containing mixed extracts of fowl and broiler chickens.
또한 본 발명의 목적은 지실 및 육계의 복합 추출물을 유효성분으로 포함하는 알레르기성 피부염 개선용 화장료 조성물을 제공하는 것이다. Another object of the present invention is to provide a cosmetic composition for improving allergic dermatitis, which comprises a combined extract of fowl and broiler chickens as an active ingredient.
상기 목적을 달성하기 위하여 본 발명은 지실 및 육계의 복합 추출물을 유효성분으로 포함하는 알레르기성 피부염 예방 또는 치료용 약학적 조성물을 제공한다. In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating allergic dermatitis, which comprises a combined extract of feces and broiler chickens as an active ingredient.
또한 본 발명은 상기 복합 추출물이 물 또는 알코올을 추출용매로 하여 추출된 알레르기성 피부염 예방 또는 치료용 약학적 조성물을 제공한다. The present invention also provides a pharmaceutical composition for preventing or treating allergic dermatitis, wherein the complex extract is extracted with water or an alcohol as an extraction solvent.
또한 본 발명은, 상기 복합 추출물이 지실 및 육계의 추출물을 1: 0.5 내지 1: 5 중량비로 혼합한 것인 알레르기성 피부염 예방 또는 치료용 약학적 조성물을 제공한다. The present invention also provides a pharmaceutical composition for preventing or treating allergic dermatitis, wherein the combined extract is a mixture of fowl and broiler chick extracts at a weight ratio of 1: 0.5 to 1: 5.
또한 본 발명은 상기 복합 추출물이 부종의 억제하는 것인 알레르기성 피부염 예방 또는 치료용 약학적 조성물을 제공한다. The present invention also provides a pharmaceutical composition for preventing or treating allergic dermatitis, wherein the combined extract is suppressed edema.
또한 본 발명은 상기 알레르기성 피부염이 접촉성 피부염 또는 아토피 피부염인 알레르기성 피부염 예방 또는 치료용 약학적 조성물을 제공한다. The present invention also provides a pharmaceutical composition for preventing or treating allergic dermatitis, wherein the allergic dermatitis is contact dermatitis or atopic dermatitis.
또한 본 발명은 지실 및 육계의 복합 추출물을 유효성분으로 포함하는 알레르기성 피부염 예방 또는 개선용 건강기능식품을 제공한다. The present invention also provides a health functional food for preventing or ameliorating allergic dermatitis, which comprises a combined extract of feces and broiler chickens as an active ingredient.
또한 본 발명은 상기 복합 추출물이 지실 및 육계의 추출물을 1: 0.5 내지 1: 5 중량비로 혼합한 것인 알레르기성 피부염 예방 또는 개선용 건강기능식품을 제공한다. The present invention also provides a health functional food for preventing or ameliorating allergic dermatitis, wherein the complex extract is a mixture of foliar and broiler chick extracts at a weight ratio of 1: 0.5 to 1: 5.
또한 본 발명은 지실 및 육계의 복합 추출물을 유효성분으로 포함하는 알레르기성 피부염 개선용 화장료 조성물을 제공한다. The present invention also provides a cosmetic composition for improving allergic dermatitis, which comprises a combined extract of feces and broiler chickens as an active ingredient.
또한 본 발명은, 상기 복합 추출물은 지실 및 육계의 추출물을 1: 0.5 내지 1: 5 중량비로 혼합한 것인 알레르기성 피부염 개선용 화장료 조성물을 제공한다. In addition, the present invention provides a cosmetic composition for improving allergic dermatitis, wherein the combined extract is obtained by mixing the extracts of fowl and broiler chickens at a weight ratio of 1: 0.5 to 1: 5.
본 발명의 지실 및 육계의 혼합 추출물은 알레르기 원인 물질에 의해 유발된 피부 부종을 효과적으로 억제할 수 있으므로, 알레르기성 피부염을 예방 또는 치료하는 효과가 있다. The mixed extract of the feces and broiler of the present invention can effectively inhibit skin edema induced by an allergen causing substance, and thus has an effect of preventing or treating allergic dermatitis.
도 1은 아토피 피부염 동물모델에서 지실 및 육계의 복합 추출물과 지실 단일 추출물(비교예 1), 육계 단일 추출물(비교예 2)의 귀 부종 억제 효과를 확인한 결과를 나타낸 도이다. FIG. 1 is a graph showing the results of confirming the effect of suppressing ear edema in a combination of foliar and broiler complex extracts, a fibrillar single extract (Comparative Example 1), and a broiler chick single extract (Comparative Example 2) in an atopic dermatitis animal model.
본 발명은 지실 및 육계의 복합 추출물을 포함하는 알레르기성 피부염 예방 또는 치료용 약학적 조성물을 제공한다. The present invention provides a pharmaceutical composition for the prevention or treatment of allergic dermatitis, which comprises a complex extract of fusarium and broiler chickens.
본 발명의 지실 및 육계의 복합 추출물은 천연 생약제의 추출물이므로 세포독성이 없으며, 알레르기성 피부염에 의해서 유발되는 부종을 효과적으로 억제할 수 있다. Since the combined extract of feces and broiler of the present invention is an extract of natural herbal medicine, it is free from cytotoxicity and effectively suppress edema caused by allergic dermatitis.
상기 복합 추출물은 물, 알코올, 에틸아세테이트, 글리세린, 에틸렌글리콜, 프로필렌글리콜, 부틸렌글리콜 및 이들의 혼합용매(예를 들어, 함수알코올, 함수글리세린, 함수에틸렌글리콜, 함수프로필렌글리콜, 함수 부틸렌글리콜)중에서 선택된 것일 수 있고, 물, 탄소수 1 내지 4의 무수알코올 또는 함수알코올에서 선택된 용매로 추출되는 것이 바람직하다. 여기서, 탄소수 1 내지 4의 알코올은 메탄올, 에탄올, n-프로판올, iso-프로판올, n-부탄올, iso-부탄올, tert-부탄올일 수 있으며, 바람직하게는 에탄올일 수 있다. The combined extract may contain at least one compound selected from the group consisting of water, alcohols, ethyl acetate, glycerin, ethylene glycol, propylene glycol, butylene glycol and mixed solvents thereof (e.g., functional alcohols, hydroglycerin, ), And it is preferably extracted with a solvent selected from water, anhydrous alcohol having 1 to 4 carbon atoms or hydrated alcohol. Here, the alcohol having 1 to 4 carbon atoms may be methanol, ethanol, n-propanol, iso-propanol, n-butanol, iso-butanol or tert-butanol, preferably ethanol.
상기 에탄올은 10 내지 100% 에탄올일 수 있고, 바람직하게는 30 또는 70% 에탄올 수용액일 수 있다. The ethanol may be 10 to 100% ethanol, preferably 30 or 70% ethanol aqueous solution.
상기 복합 추출물은 지실 및 육계를 1: 0.1 내지 1:10의 중량비로 혼합하여 추출한 추출물일 수 있으며, 바람직하게는 1: 0.5 내지 1:5 중량비로 혼합하여 추출한 혼합 추출물이다. The combined extract may be an extract obtained by mixing the fowl and broiler chickens at a weight ratio of 1: 0.1 to 1:10, preferably 1: 0.5 to 1: 5 by weight.
본 발명의 복합 추출물은 지실 및 육계를 혼합하여 추출한 추출물 뿐만 아니라, 지실 및 육계 각각의 성분을 추출한 후 혼합한 추출물도 포함할 수 있다. The complex extract of the present invention may include not only extracts obtained by mixing fowl and broiler chickens, but also extracts obtained by extracting components of fowl and broiler chickens.
바람직한 일 예로서 상기 복합 추출물은 지실 및 육계를 30 또는 70% 에탄올을 이용하여 추출하고 각 단일 추출물을 1:0.5 내지 1: 5 중량비로 혼합하는 것이 바람직하다. As a preferred example, it is preferable that the combined extract is extracted with 30 or 70% ethanol and the single extracts are mixed at a weight ratio of 1: 0.5 to 1: 5.
본 발명의 지실 및 육계의 복합추출물은 알레르기성 피부염을 효과적으로 치료할 수 있으며, 상기 알레르기성 피부염은 알레르기가 원인이되어 발병하는 피부병을 제한없이 포함할 수 있고, 바람직하게는 접촉성 피부염 또는 아토피 피부염일 수 있다. The combined extract of feces and broiler chickens of the present invention can effectively treat allergic dermatitis. The allergic dermatitis can include without limitation any dermatosis caused by allergy, preferably, contact dermatitis or atopic dermatitis .
상기 지실 및 육계의 혼합 추출물은 하기의 단계를 포함하는 제조방법에 의해 제조되는 것이 바람직하나 이에 한정되지 않는다. The fowl and broiler mixed extracts are preferably prepared by a method comprising the following steps, but are not limited thereto.
(1) 지실 및 육계를 건조 후 세절하는 단계;(1) drying and finely dividing the feed and broiler chicks;
(2) 세절한 지실 및 육계에 추출용매를 가하여 추출하고 추출물을 얻는 단계;(2) Extracting the extracted seedlings and broiler chickens with an extraction solvent to obtain an extract;
(3) 추출물을 식힌 후 여과하는 단계;(3) cooling and extracting the extract;
(4) 여과된 추출물을 농축한 후 건조하는 단계(4) a step of concentrating and drying the filtered extract
(5) 건조된 지실 및 육계의 추출물을 분말상태로 제조한 후 혼합하는 단계.(5) a step of preparing dried ground beef and broiler chick extract in powder form and mixing.
상기 단계 (1)에 사용되는 지실 및 육계는 재배한 것 또는 시판되는 것 등을 제한없이 사용할 수 있다.The seedlings and broilers used in step (1) above may be cultivated or marketed without limitation.
상기 단계 (2)의 추출은 진탕 추출, Soxhlet 추출 또는 환류 추출 방법을 이용할 수 있으나 이에 한정되지 않는다. 추출온도는 50 내지 120 ℃인 것이 바람직하며, 90 내지 95℃인 것이 더욱 바람직하다. 또한, 추출시간은 2 내지 5시간인 것이 바람직하며, 상기 추출은 1 내지 5회 수행할 수 있다. The extraction of step (2) may be performed by shaking extraction, Soxhlet extraction, or a reflux extraction method, but is not limited thereto. The extraction temperature is preferably 50 to 120 ° C, more preferably 90 to 95 ° C. In addition, the extraction time is preferably 2 to 5 hours, and the extraction may be performed 1 to 5 times.
상기 (3) 단계의 여과는 100~ 500메쉬를 이용하여 여과할 수 있고, 바람직하게는 100~ 300메쉬를 이용할 수 있다. The filtration in the step (3) may be performed using 100 to 500 mesh, preferably 100 to 300 mesh.
상기 (4) 단계의 여과된 추출물은 1 내지 5일간 실온에서 방치하여 침전물을 가라앉히는 공정을 거칠 수 있으며, 이를 통해 얻어진 침전물 여과하는 공정을 추가적으로 포함할 수 있다. The filtered extract of step (4) may be subjected to a step of allowing the precipitate to settle by allowing it to stand at room temperature for 1 to 5 days, and may further include a step of filtering the obtained precipitate.
상기 (4) 단계의 농축은 10 내지 100℃에서 이루어질 수 있으며 진공감압농축기 또는 진공회전증발기를 이용하여 농축할 수 있고, 최종적으로 10~30brix, 바람직하게는 15brix가 되도록 농축하는 것이 바람직하다. 또한 상기 건조는 감압건조, 진공건조, 비등건조, 분무건조 또는 동결건조 방법을 이용하는 것이 바람직하고, 동결건조 방법이 더욱 바람직하다. The concentration in the step (4) may be performed at 10 to 100 ° C and may be performed using a vacuum decompression condenser or a vacuum rotary evaporator, and is preferably 10 to 30 brix, preferably 15 brix. In addition, the above-mentioned drying is preferably carried out by vacuum drying, vacuum drying, boiling drying, spray drying or freeze drying, more preferably freeze-drying.
본 발명에서, 의약 조성물은 연고, 겔, 크림, 패취 및 분무제로 이루어지는 군으로부터 선택되는 제형일 수 있다. 또한, 상기 의약 조성물은 경구용 제제 또는 주사용 제제일 수 있다.In the present invention, the pharmaceutical composition may be a formulation selected from the group consisting of ointments, gels, creams, patches and sprays. In addition, the above pharmaceutical composition may be an oral preparation or a main ingredient.
상기 경구용 제제는 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸, 현탁제, 내용액제, 유제 또는 시럽제이고, 상기 주사용 제제는 멸균 주사제 형태의 제형일 수 있다.The oral preparation may be a powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol, suspension, solution, emulsion or syrup, and the injectable preparation may be in the form of a sterile injectable preparation.
본 발명의 약학 조성물은 약학적으로 허용되는 담체를 첨가하여 제제화할 수 있으며, 제제화에 관한 내용은 Remington's Pharmaceutical Science(최근판), Mack Publishing Company, Easton PA의 문헌을 참조할 수 있다. 상기 약학적으로 허용 가능한 담체는 의약 발명 부분에 속하는 통상의 기술자에게 의약 조성물 제조시 통상적으로 사용되는 것을 의미한다. 예를 들어, 락토오즈, 덱스트로오즈, 수크로오스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오즈, 메틸 셀룰로오즈, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등이 있다. 또한, 약학적으로 허용되는 담체는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 포함한다. The pharmaceutical composition of the present invention can be formulated by adding a pharmaceutically acceptable carrier. For formulation, refer to Remington's Pharmaceutical Science (recent edition), Mack Publishing Company, Easton PA. The pharmaceutically acceptable carrier means those conventionally used in the manufacture of a pharmaceutical composition for a person skilled in the art to which the present invention belongs. For example, there may be mentioned lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, Water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. Pharmaceutically acceptable carriers also include diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, and the like.
예를 들어, 국소투여에 적합한 약학적 담체 및/또는 부형제는 본 발명에 따르면 피부 투여용 약학제제(예를 들어 피부질환 치료제)와 관련하여 해당 기술 분야의 당업자에 공지된 통상적인 담체 및/또는 부형제인 것이 바람직하다. For example, a pharmaceutical carrier and / or excipient suitable for topical administration may be a conventional carrier known to those skilled in the art in connection with the pharmaceutical preparation for skin administration (for example, a skin disease treatment) according to the present invention and / It is preferably an excipient.
경구 투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제 및 캡슐제 등이 포함되며, 이러한 고형 제제는 본 발명의 약학적 조성물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 탄산칼슘, 수크로스, 락토오스 및 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 마그네슘, 스티레이드, 탈크 같은 윤활제도 사용될 수 있다. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like. Such solid preparations can be prepared by incorporating into the pharmaceutical composition of the present invention at least one or more excipients such as starch, calcium carbonate, sucrose, Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium, stearide, and talc may also be used.
경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제 및 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제 및 보존제 등이 포함될 수 있다. Liquid preparations for oral administration include suspensions, solutions, emulsions and syrups. Various excipients such as wetting agents, sweeteners, fragrances and preservatives may be included in addition to water and liquid paraffin, which are commonly used simple diluents. have.
피부 투여를 위해 언급할 수 있는 예로는 더스팅 파우더, 에멀젼, 현탁액, 오일, 스프레이, 연고, 그리지 연고, 크림 페이스트, 겔, 폼, 또는 용액을 생성시키는데 적합하고, 경피 약물 전달체(TTS: Transdermal therapeuticsystem)에 적합한 담체 및/또는 부형제가 있다. 본 발명의 국소용 약학제제는 반고체상 제형일 수 있으며 특히 연고(용액 연고, 현탁액 연고), 크림, 겔 또는 페이스트가 있다. 유상에 주로 사용되는 것은 지방 알콜, 예를 들면 라우릴 알코올, 세틸 알코올, 스테아릴 알코올, 지방산, 예를 들면 팔미트산 또는 스테아르산, 액상 또는 고체상 파라핀 또는 오조케라이트, 액상 내지 고체상 왁스, 예를 들면 이소프로필 미리스테이트, 천연 지방 또는 일부 합성 지방, 예를 들면 코코넛 지방산 트리글리세라이드, 경화유, 예를 들면 수소화된 피넛 또는 캐스터 오일, 또는 글리세롤의 지방산 부분 에스테르, 예를 들면 글리세롤 모노스테아레이트 또는 글리세롤 디스테아레이트가 있다. 적합한 유화제로는 계면활성제, 예를 들어 비이온성 계면활성제, 예를 들면 폴리알코올 또는 이것의 산화에틸렌 부가물의 지방산 에스테르, 예컨대 폴리글리세롤 지방산 에스테르 또는 폴리옥시 에틸렌 소르비탄 지방산 에스테르, 소르비탄 지방산 에스테르, 예컨대 소르비탄 올레에이트 및/또는 소르비탄 이소스테아레이트등, 이소스테아레이트, 스테롤, 또는 폴리옥시에틸렌 지방 알콜 에테르 또는 지방산 에스테르, 예를 들어 음이온성 계면활성제, 예를 들면 지방 알코올 설포네이트의 알칼리 금속염, 예컨대 나트륨라우릴 설페이트, 나트륨 세틸 설페이트 또는 나트륨 스테아릴 설페이트가 있으며 이들은 상기 지방 알코올, 예를 들면 세틸 알코올 또는 스테아릴 알코올의 존재 하에서 일반적으로 사용된다. 이 중에서도 특히 크림 건조를 방지하는 제제, 예를 들면 폴리알코올, 예컨대 글리세롤, 소르비톨, 프로필렌 글리콜 및/또는 폴리에틸렌 글리콜을 수상에 첨가하거나 또는 보존제, 향료 등을 수상에 첨가하는 것이 가능하다. Examples which may be mentioned for skin administration are suitable for the production of dusting powders, emulsions, suspensions, oils, sprays, ointments, ointments, creams, pastes, gels, foams or solutions, and may be formulated as transdermal therapeutics (TTS) ) And / or excipients. The topical pharmaceutical preparations of the present invention may be semi-solid formulations, in particular ointments (ointments, suspension ointments), creams, gels or pastes. Lactic alcohol, cetyl alcohol, stearyl alcohol, fatty acids such as palmitic acid or stearic acid, liquid or solid paraffin or ozokerite, liquid or solid waxes, for example, For example, isopropyl myristate, natural or partially synthetic fats such as coconut fatty acid triglycerides, hydrogenated oils such as hydrogenated peanut or castor oil, or fatty acid partial esters of glycerol, such as glycerol monostearate or glycerol There is distearate. Suitable emulsifiers include surfactants, such as nonionic surfactants, such as polyalcohols or fatty acid esters of ethylene oxide adducts thereof, such as polyglycerol fatty acid esters or polyoxyethylene sorbitan fatty acid esters, sorbitan fatty acid esters such as Sterol or polyoxyethylene fatty alcohol ethers or fatty acid esters such as sorbitan oleate and / or sorbitan isostearate, such as, for example, an alkali metal salt of an anionic surfactant, for example a fatty alcohol sulfonate, Such as sodium lauryl sulfate, sodium cetyl sulfate or sodium stearyl sulfate, which are generally used in the presence of the fatty alcohols described above, for example cetyl alcohol or stearyl alcohol. Among them, it is possible to add an agent for preventing the drying of the cream, for example, a polyalcohol such as glycerol, sorbitol, propylene glycol and / or polyethylene glycol to the aqueous phase or to add a preservative, perfume or the like to the aqueous phase.
본 발명의 약학제제는 무수상태의 연고일 수 있고, 국소용도에 적합하고 체온상태에서 액체인 파라핀, 특히 저점도 파라핀을 함유하거나, 또는 상기 천연지방 또는 부분합성 지방, 예를 들면, 코코넛 지방산 트리글리세라이드, 경화유, 예를 들면 수소화된 피넛 도는 캐스터 오일, 글리세롤의 지방산 부분 에스테르, 예를 들면 글리세롤 모노스테아레이트 및 디스테아레이트, 실리콘, 예를 들면 폴리메틸실록산, 예컨대 헥사메틸디실록산 도는 옥타메틸트리실록산을 함유할 수 있으며, 예를 들어 수성크림과 관련되어 있고 수분 흡수 용량을 증가시키는 지방 알코올, 그리고 스테롤, 울 왁스, 다른 유화제 및/또는 기타 첨가제를 함유할 수 있다. The pharmaceutical preparations of the present invention may be paraffinic, especially low viscosity paraffin, which may be an anhydrous ointment and which is suitable for topical use and is liquid at body temperature, or which contains the natural or partially synthetic fat, for example coconut fatty acid triglycerides Sorbitan monostearate and distearate, silicones such as polymethylsiloxane, such as hexamethyldisiloxane, or octamethyl triisostearate, such as, for example, glycerol monostearate and distearate, Siloxanes, and may contain, for example, fatty alcohols associated with aqueous creams and increasing water absorption capacity, and sterols, wool waxes, other emulsifiers and / or other additives.
그러나, 상기 열거된 약제학적으로 허용되는 담체 등으로 본 발명이 한정되는 것은 아니며, 이들은 단지 예시에 불과하다.However, the present invention is not limited to the above-listed pharmaceutically acceptable carriers and the like, and these are merely illustrative.
상기 약학 조성물에 함유되는 지실 및 육계 복합 추출물의 적용량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 경우에 따라 적절하게 선택될 수 있다. 예를 들면, 상기 지실 및 육계의 복합 추출물은 1일 0.0001 내지 1000 mg/kg으로, 바람직하게는 0.1 내지 1000 mg/kg의 용량으로 경구 투여될 수 있으며, 상기 적용은 하루에 한번 또는 수회 나누어 적용할 수도 있다. 또한, 상기 약학 조성물은 조성물 총 중량에 대하여 상기 지실 및 육계 복합 추출물을 0.0001 내지 50 중량%로 포함할 수 있다. 상기 약학 조성물은 인간 등의 포유동물에 다양한 경로로, 예를 들면, 경피, 경구, 정맥, 근육, 또는 피하 주사에 의해 적용될 수 있다. The amount of the fecal and broiler complex extract to be contained in the pharmaceutical composition varies depending on the condition and body weight of the patient, the severity of the disease, the drug form, the administration route and the period, but may be appropriately selected depending on the case. For example, the combined extract of fowl and broiler chickens may be orally administered at a dose of 0.0001 to 1000 mg / kg per day, preferably 0.1 to 1000 mg / kg per day, and the application may be applied once or several times per day You may. In addition, the pharmaceutical composition may contain 0.0001 to 50% by weight of the fowl and broiler complex extract based on the total weight of the composition. The pharmaceutical compositions may be applied to mammals, such as humans, by a variety of routes, for example, transdermal, oral, intravenous, intramuscular, or subcutaneous injection.
또한 본 발명의 의약조성물은 지실 및 육계의 복합 추출물 외에 알레르기성 피부염의 개선, 완화, 치료 또는 예방을 나타내는 유효성분을 1종 이상 함유할 수 있다.In addition, the pharmaceutical composition of the present invention may contain at least one active ingredient which exhibits improvement, relief, treatment or prevention of allergic dermatitis in addition to a complex extract of fecal and broiler chickens.
또한 본 발명의 의약조성물은 알레르기성 피부염의 개선, 완화, 치료 또는 예방을 위하여 단독으로, 또는 수술, 호르몬 치료, 약물 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.In addition, the pharmaceutical composition of the present invention can be used alone, or in combination with methods using surgery, hormone therapy, drug therapy and biological response modifiers, for the amelioration, alleviation, treatment or prevention of allergic dermatitis.
또한 본 발명은 지실 및 육계의 복합 추출물을 포함하는 알레르기성 피부염 예방 또는 개선용 건강기능식품을 제공한다. The present invention also provides a health functional food for preventing or ameliorating allergic dermatitis, which comprises a combined extract of fusarium and broiler chickens.
상기 복합 추출물은 지실 및 육계를 1: 0.1 내지 1:10의 중량비로 혼합하여 추출한 추출물일 수 있으며, 바람직하게는 1: 0.5 내지 1:5 중량비로 혼합하여 추출한 복합 추출물이다. The combined extract may be an extract obtained by mixing the fowl and broiler chickens at a weight ratio of 1: 0.1 to 1:10, preferably 1: 0.5 to 1: 5 by weight.
바람직한 일 예로서 상기 복합 추출물은 지실 및 육계를 30 또는 70% 에탄올을 이용하여 추출하고 각 단일 추출물을 1:0.5 내지 1: 5 중량비로 혼합하는 것이 바람직하다. As a preferred example, it is preferable that the combined extract is extracted with 30 or 70% ethanol and the single extracts are mixed at a weight ratio of 1: 0.5 to 1: 5.
상기 건강기능식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있고, 그 밖에 천연 과일쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. The health functional food may contain flavoring agents such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and thickening agents (cheese, chocolate etc.), pectic acid and its salts, alginic acid and its salts, Organic acid, protective colloid thickener, pH adjusting agent, stabilizer, antiseptic, glycerin, alcohol, carbonating agent used in carbonated beverages, and the like, as well as pulp for producing natural fruit juice and fruit juice drinks and vegetable drinks ≪ / RTI > These components may be used independently or in combination.
상기 건강기능식품은 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 껌류, 아이스크림류, 스프, 음료수, 차, 기능수, 드링크제, 알콜 음료 및 비타민 복합제 중 어느 하나의 형태일 수 있다.The health functional food may be any one of meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, drink, alcoholic beverage, .
상기 건강기능식품은 식품첨가물을 추가로 포함할 수 있으며, "식품첨가물"로서의 적합여부는 다른 규정이없는 한 식품의약품안정청에 승인된 식품첨가물공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.The health functional food may further contain food additives and the suitability for "food additives" is not limited to those specified in the General Regulations of the Food Additives Ordinance approved by the Food and Drug Administration, And standards.
상기 "식품첨가물공전"에 수재된 품목으로 예를 들어, 케톤류, 글리신, 구연산칼륨, 니코틴산, 계피산 등의 화학적 합성품, 감색소, 감초추출물, 결정셀롤로오스, 고랭색소, 구아검 등의 천연첨가물, L-글루타민산나트륨제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합 제제류들을 들 수 있다.Examples of the products listed in the above-mentioned "food additives" include natural products such as ketones, chemical products such as glycine, potassium citrate, nicotinic acid and cinnamic acid, coloring matter, licorice extract, crystalline cellulosic, high- , A sodium L-glutamate preparation, a noodle-added alkaline agent, a preservative preparation, a tar coloring agent, and the like.
본 발명의 건강기능식품을 제조하는 과정에서 음료를 포함한 식품에 첨가되는 본 발명의 지실 및 육계의 복합 추출물은 필요에 따라 그 함량을 적절히 가감할 수 있으며, 바람직하게는 전체 식품 100 중량%에 대하여 1 내지 15 중량% 포함되도록 첨가하는 것이 바람직하다.In the process for producing the health functional food of the present invention, the compound extracts of the feces and broiler chickens of the present invention, which are added to foods containing beverages, can be appropriately added or decreased as required, and preferably about 100% 1 to 15% by weight.
또한 본 발명은 지실 및 육계의 복합 추출물을 포함하는 알레르기성 피부염 개선용 화장료 조성물을 제공한다. The present invention also provides a cosmetic composition for improving allergic dermatitis, which comprises a combined extract of flaxseed and broiler chicks.
상기 복합 추출물은 지실 및 육계를 1: 0.1 내지 1:10의 중량비로 혼합하여 추출한 추출물일 수 있으며, 바람직하게는 1: 0.5 내지 1:5 중량비로 혼합하여 추출한 복합 추출물이다. The combined extract may be an extract obtained by mixing the fowl and broiler chickens at a weight ratio of 1: 0.1 to 1:10, preferably 1: 0.5 to 1: 5 by weight.
바람직한 일 예로서 상기 복합 추출물은 지실 및 육계를 1: 0.5 내지 1:5 중량비로 혼합하여 30 또는 70% 에탄올을 이용하여 추출하는 것이 바람직하다. As a preferred example, it is preferable that the combined extract is extracted with 30 or 70% ethanol by mixing the fowl and broiler chickens at a weight ratio of 1: 0.5 to 1: 5.
본 발명에서, 상기 화장료 조성물은 유연화장수, 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 아이에센스, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 파우더, 바디로션, 바디크림, 바디오일, 바디에센스, 메이크업 베이스, 파운데이션, 염모제, 샴푸, 린스 및 바디 세정제로 이루어지는 군으로부터 선택되는 제형일 수 있다.In the present invention, the cosmetic composition of the present invention can be used in cosmetics such as soft longevity, astringent lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, pack, powder, body lotion, A body oil, a body essence, a makeup base, a foundation, a hair dye, a shampoo, a rinse, and a body cleansing agent.
본 발명의 화장료 조성물은 상기 지실 및 육계 복합 추출물을 사용하여 통상의 화장료 제조방법에 따라, 다양한 형태로 제조될 수 있으며, 화장료 조성물 분야에서 통상적으로 사용되는 안정화제, 용해화제, 비타민, 안료, 및 향료와 같은 통상적인 보조제를 포함할 수 있다.The cosmetic composition of the present invention can be prepared in various forms according to a conventional cosmetic preparation method using the above-mentioned flax and broiler complex extract, and can be used as a stabilizer, a dissolving agent, a vitamin, a pigment, And customary adjuvants such as perfumes.
또한, 화장료 조성물이 상기 지실 및 육계의 복합 추출물을 함유하는 향장 제품, 샴푸, 헤어로션, 헤어크림, 헤어젤 등의 형태로 제조될 경우, 통상의 클렌징액, 수렴액 및 보습액으로 희석하여 사용될 수 있다.Also, when the cosmetic composition is prepared in the form of a perfume product, a shampoo, a hair lotion, a hair cream, a hair gel or the like containing the complex extract of the feces and broiler chicks, it can be diluted with a usual cleansing solution, have.
본 발명의 화장료 조성물은 특히 화장수, 로션, 크림, 에센스 형태로 제조되는 것이 바람직하다. The cosmetic composition of the present invention is particularly preferably prepared in the form of a lotion, lotion, cream, or essence.
본 발명의 화장료 조성물에서 지실 및 육계의 복합추출물은 화장료 조성물의 총 액상 중량에 대하여 0.1중량%~10중량%의 양을 화장료에 첨가될 수 있고, 또한 화장료 조성물의 총 건조중량에 대하여 0.001∼5 중량%, 바람직하게는 0.01∼3 중량%의 양으로 화장료에 첨가될 수 있다.In the cosmetic composition of the present invention, the foliar and broiler complex extract may be added to the cosmetic composition in an amount of 0.1% by weight to 10% by weight with respect to the total liquid weight of the cosmetic composition, and 0.001 to 5 By weight, preferably 0.01 to 3% by weight, based on the total weight of the cosmetic composition.
이상 본 명세서에 기재된 수치값은 달리 명시되어 있지 않은 한 균등범위까지 포함하는 것으로 해석되어야 한다. The numerical values set forth herein should be construed to cover equivalent ranges unless otherwise indicated.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예, 제제예를 제시한다. 그러나 하기의 실시예, 제제예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 실시예 또는 제제예에 의해 본 발명의 내용이 한정되는 것은 아니다.Best Mode for Carrying Out the Invention Hereinafter, preferred examples and formulation examples are shown to facilitate understanding of the present invention. However, the following examples and preparations are provided only for the purpose of easier understanding of the present invention, and the contents of the present invention are not limited by the examples or preparation examples.
실시예 1. 지실 및 육계의 복합 추출물의 면역 억제 효과Example 1 Immunosuppressive Effect of Combined Extracts of Zyseal and Broiler Chicks
1.1 지실 및 육계의 복합 추출물 제조1.1 Manufacture of complex extracts of root and broiler
지실은 약수당(서울 동대문구)에서 육계는 제천한방약초(충북 제천시)에서 구입하여 사용하였다. 지실 62.5g 및 육계 37.5g에 각각 30% 에탄올을 10배 중량 첨가하고 90~95℃에서 3시간 동안 2회 반복하여 추출하였다. 추출된 지실 및 육계의 단일 추출물을 여과지로 감압 여과한 후 여과액을 감압농축기에서 15 brix로 감압농축하였다. 얻어진 농축액을 예비동결기로 -45℃에서 20분간 예비 동결한 후, 동결건조기로 동결건조하여 분말상태로 제조하였다. 이후 제조된 지실 및 육계의 분말을 혼합하여 복합 추출물 분말을 제조하였다. Chicken was purchased from Jecheon Herbang Herb (Jecheon City, Chungbuk) and used in the medicines (Dongdaemun-gu, Seoul). 30% ethanol was added 10 times by weight to 62.5 g of fibrin and 37.5 g of broiler chickens, respectively, and extracted twice at 90 to 95 캜 for 3 hours. The extracts of the extracts from broiler chickens and broiler chickens were filtered with a filter paper, and the filtrate was concentrated under reduced pressure to 15 brix in a vacuum concentrator. The resulting concentrate was preliminarily frozen at -45 캜 for 20 minutes in a preliminary freezer, and then lyophilized with a freeze dryer to prepare a powder. The resulting extracts of broiler chickens and broiler chicks were mixed to prepare a complex extract powder.
상기 복합 추출물의 제조를 위해 사용된 지실 및 육계의 함량은 하기 표 1과 같다.Table 1 below shows the content of flax and broilers used for the preparation of the complex extract.
[표 1][Table 1]
1.2 지실 및 육계의 단일 추출물 제조 1.2 Manufacture of single extracts of root and broiler
지실과 육계는 염증 개선효과가 있는 것으로 알려져 있으므로, 지실 및 육계의 복합 추출물이 단일 추출물과 비교하여 시너지 효과를 나태내는 지 비교 실험을 통해 확인하였다. 지실, 육계의 단일 추출물은 각각 지실 100g, 육계 100g을 사용한 것을 제외하고는 1.1의 복합추출물과 동일한 방법으로 제조하였다. Since it is known that Zyseil and broiler chickens have an inflammation - improving effect, comparative experiments have confirmed whether the combined extracts of Zysei and broiler chicks are synergistic compared with single extracts. The single extracts of Zysei and broiler were prepared in the same manner as the compound extracts of 1.1 except that 100g of zygosan and 100g of broth were used respectively.
지실 단일 추출물(비교예 1) 및 육계 단일 추출물(비교예 2)의 추출물에 포함된 지실 및 육계의 함량은 하기 표 2와 같다.The content of flax and broiler chickens contained in the extracts of the persimmon single extract (Comparative Example 1) and the broiler mono extract (Comparative Example 2) are shown in Table 2 below.
[표 2][Table 2]
1.3 복합 추출물의 피부 면역반응 억제 효과 확인1.3 Confirmation of skin irritation inhibitory effect of compound extract
복합 추출물의 피부 면역반응 억제 효과를 확인하기 위하여 2,4 디니트로플로오로벤젠(2,4-dinitrofluorobenzene)(이하, DNFB)로 유발한 접촉성 피부염 모델을 아토피 피부염의 동물 모델로 사용하였다. T-세포 매개성 염증반응 화학물질인 DNFB의 도포는 마우스에 아토피와 비슷한 지연형 접촉성 피부염을 유발시키며, 반복 노출 시 1형 헬퍼 T-세포 매개성 염증세포의 침윤에 의한 피부 부종과 피부 조직의 비후가 나타나므로, 아토피 피부염을 비록한 알레르기성 피부염 연구에 널리 이용되고 있다. 실험동물은 생후 7주령 된 암컷 BALB/c 생쥐를 (주)샘타코 BIO KOREA 에서 구입하여 사용하였다. To investigate the inhibitory effect of compound extract on skin immune response, contact dermatitis model induced by 2,4-dinitrofluorobenzene (DNFB) was used as an animal model of atopic dermatitis. The application of DNFB, a T-cell mediated inflammatory reaction chemical, induces delayed contact dermatitis similar to atopy in mice. In the case of repeated exposure, skin irritation caused by infiltration of T- Of allergic dermatitis, atopic dermatitis is widely used for the study of allergic dermatitis . Female BALB / c mice were purchased from Samtaco BIO KOREA at 7 weeks of age.
실험동물을 온도 22±2℃, 습도 55±10%, 조명시간 12시간(07:00~19:00) 조건 하에 1주일 이상 적응시킨 후 실험에 사용하였으며, 실험기간 동안 음식과 물은 충분히 공급하였고, 실험동물이 자유롭게 먹을 수 있도록 하였다.Experimental animals were adapted for more than 1 week under conditions of temperature 22 ± 2 ℃, humidity 55 ± 10% and illumination time 12 hours (07: 00 ~ 19: 00) And allowed the animals to eat freely.
피부에서의 면역반응을 확인하기 위하여 실험동물의 등을 실험 전날 제모제로 제모하였다. 0일 및 1일차에 아세톤-올리브오일(acetone-olive oil)(4:1)에 녹인 1% DNFB 용액 20μl를 쥐의 등에 균일하게 도포하여 알레르기성 피부염을 유발하였다. In order to confirm the immune response in the skin, the back of the experimental animal was epilated in the day before the experiment. On day 0 and day 1, 20 μl of 1% DNFB solution dissolved in acetone-olive oil (4: 1) was uniformly applied to rats to induce allergic dermatitis.
지실 및 육계의 복합 추출물, 지실 단일 추출물, 육계 단일 추출물은 실험 0일차부터 6일까지 7일 동안 하루에 2번 증류수에 용해하여 100 mg/kg로 경구투여하였다. 1차 증류수를 10ml/kg로 경구투여한 마우스를 대조군으로 하였으며, 양성대조군으로 항염증 효과를 갖는 프레드니솔론(prednisolone)을 10 mg/kg 경구투여하였다. The combined extracts of Zysei and broiler, Zygocyma single extract and Broiler chrysanthemum extract were orally administered at 100 mg / kg in distilled water twice daily for 7 days from the 0th to 6th day of the experiment. The mice were orally administered at a dose of 10 ml / kg of primary distilled water. Control mice were treated with prednisolone (prednisolone) at a dose of 10 mg / kg as a positive control.
실험 6일차에는 추가적으로 아세톤-올리브 오일(4:1)에 녹인 0.5% DNFB 용액 20μl를 쥐의 오른쪽 귀에 도포하였다. 귀의 두께는 도포 직전과 도포 24시간 뒤에 공학용 켈리퍼(engineering caliper)로 측정하였으며, 부종의 크기는 귀 두께의 증가로 평가하였다. On the sixth day of experiment, 20 μl of a 0.5% DNFB solution dissolved in acetone-olive oil (4: 1) was further applied to the right ear of rats. Ear thickness was measured with an engineering caliper immediately prior to application and 24 hours after application and the size of edema was assessed as an increase in ear thickness.
결과를 도 1 및 표 3에 나타내었다. The results are shown in FIG. 1 and Table 3.
[표 3][Table 3]
도 1 및 표 3에서 확인할 수 있는 것과 같이, 지실 및 육계의 복합 추출물은 대조군에 비하여 DNFB로 유발한 접촉성 피부염 모델에서 유의하게 귀의 부종을 억제하였다. 보다 구체적으로 0.5% DNFB 용액을 바른 후 24시간 뒤 대조군의 귀 두께는 0.16±0.02mm 증가한 반면 복합 추출물 100mg/kg 투여군의 귀 두께는 0.07±0.01mm 증가하여 귀 부종이 55.8% 억제되었다(p<0.05). 이와 비교하여 비교예 1인 지실 단일 추출물 100mg/kg 투여군과 비교예 2의 육계 단일 추출물 100 mg/kg 투여군은 각각 21.1%, 3.7%의 귀 부종 억제효과를 나타내었다. 즉 지실과 육계의 단일 추출물은 대조군과 대비하여 유의한 차이를 보이지 않았으며, 지실 및 육계의 복합 추출물에 비하여 현저히 낮은 부종억제 효과를 보이는 것으로 나타났다. 이를 통해 지실 및 육계의 복합 추출물은 지실, 육계의 단일 추출물과 비교하여 현저히 향상된 부종 억제 효과가 있는 것을 확인하였다. As can be seen from Figs. 1 and 3, the combined extracts of fowl and broiler chicks significantly inhibited ear edema in the DNFB-induced contact dermatitis model compared with the control group. More specifically, the ear thickness after applying a 0.5% DNFB solution 24 hours later the control group 0.16 ± 0.02mm to the ear thickness of the composite Extract 100mg / kg administered group, while an increase is increased 0.07 ± 0.01mm was 55.8% inhibited ear edema (p < 0.05 ). Compared with the control group, the group administered with 100 mg / kg of the single extract of Zysexil and the group administered with 100 mg / kg of the single extract of the broiler group of Comparative Example 2 showed 21.1% and 3.7% of the effect of suppressing ear edema, respectively. In other words, there was no significant difference between the single extracts of Zyseil and broiler chicks compared to the control group, and it showed a remarkably low edema suppression effect compared with the combined extracts of Zysei and broiler chicks. The results showed that the combined extracts of Zyseil and broiler chicks had remarkably improved edema inhibition effect compared to the single extract of Zysei and broiler chicks.
또한 지실 및 육계의 복합 추출물은 양성대조군인 프레드니솔론과 비교하여 유사한 정도의 부종 억제 효과를 나타냈다. 프레드니솔론은 화합물이므로 이를 제조, 정제하는데 드는 공정을 고려하면 본 발명의 복합 추출물은 프레드니솔론에 비하여 제조 공정상의 유용성을 가지며, 이를 대체할 수 있을 만큼의 면역 반응 억제 효과를 갖는 것을 알 수 있다. Compared with the positive control, prednisolone showed a similar degree of edema inhibition. Since the compound of prednisolone is a compound, considering the process for preparing and purifying it, it can be seen that the compound extract of the present invention has a usefulness in manufacturing process as compared with prednisolone and has an immune response inhibiting effect enough to replace it.
제제예 1. 의약품의 제조Preparation Example 1. Preparation of medicines
1.1 산제의 제조1.1 Manufacture of Powder
지실 및 육계의 복합 추출물 100mgCombined extract of flaxseed and broiler 100mg
유당 100mgLactose 100mg
탈 10mg10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above components are mixed and filled in airtight bags to prepare powders.
1.2 정제의 제조1.2 Preparation of tablets
지실 및 육계의 복합 추출물 100mgCombined extract of flaxseed and broiler 100mg
옥수수전분 100mg
유당 100mgLactose 100mg
스테아린산 마그네슘 2mgMagnesium stearate 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
1.3 캡슐제의 제조1.3 Preparation of capsules
지실 및 육계의 복합 추출물 100mgCombined extract of flaxseed and broiler 100mg
옥수수전분 100mg
유당 100mgLactose 100mg
스테아린산 마그네슘 2mgMagnesium stearate 2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 정제를 제조한다.The above components are mixed according to a conventional capsule preparation method and filled into gelatin capsules to prepare tablets.
1.4 주사제의 제조1.4 Manufacture of Injection
지실 및 육계의 복합 추출물 100mgCombined extract of flaxseed and broiler 100mg
주사용 멸균 증류수 적량Sterile sterilized water for injection
pH 조절제 적량pH adjuster
통상의 주사제의 제조방법에 따라 1 앰플당(2ml) 상기의 성분 함량으로 제조한다.(2 ml) per 1 ampoule in accordance with the usual injection method.
1.5 액제의 제조1.5 Manufacture of liquids
지실 및 육계의 복합 추출물 100mgCombined extract of flaxseed and broiler 100mg
설탕 20gSugar 20g
이성화당 20g20g per isomer
레몬향 적량Lemon incense quantity
정제수를 가하여 전체 1,00ml로 맞추었다. 통상의 액제의 제조방법에 따라 상기의 성분을 혼합한 다음, 갈색병에 충전하고 멸균시켜 액제를 제조한다.Purified water was added to make a total of 1,00 ml. The above components are mixed according to a usual method for producing a liquid agent, and then filled in a brown bottle and sterilized to prepare a liquid agent.
제제예 2. 건강기능식품의 제조Formulation Example 2. Preparation of Health Functional Foods
지실 및 육계의 복합 추출물 100mgCombined extract of flaxseed and broiler 100mg
비타민 혼합물 적량Vitamin mixture quantity
비타민 A 아세테이트 70 ㎍70 [mu] g of vitamin A acetate
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎0.13 mg vitamin B1
비타민 B2 0.15 ㎎0.15 mg of vitamin B2
비타민 B6 0.5 ㎎0.5 mg vitamin B6
비타민 B12 0.2 ㎍0.2 [mu] g vitamin B12
비타민 C 10 ㎎10 mg vitamin C
비오틴 10 ㎍Biotin 10 μg
니코틴산아미드 1.7 ㎎Nicotinic acid amide 1.7 mg
엽산 50 ㎍50 ㎍ of folic acid
판토텐산 칼슘 0.5 ㎎Calcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture quantity
황산제1철 1.75 ㎎1.75 mg of ferrous sulfate
산화아연 0.82 ㎎0.82 mg of zinc oxide
탄제1인산칼륨 15 ㎎Calcium monophosphate 15 mg
제2인산칼슘 55 ㎎Secondary calcium phosphate 55 mg
구연산칼륨 90 ㎎Potassium citrate 90 mg
탄산칼슘 100 ㎎100 mg of calcium carbonate
염화마그네슘 24.8 ㎎24.8 mg of magnesium chloride
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강기능식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강기능식품 제조방법에 따라 상기의 성분을 혼합한 다음, 통상의 방법에 따라 건강기능식품 조성물 제조(예, 영양캔디 등)에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a component suitable for a health functional food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above components may be mixed And then used in the manufacture of a health functional food composition (for example, a nutritious candy, etc.) according to a conventional method.
제제예 3. 건강기능성 음료의 제조Formulation Example 3. Preparation of Health Functional Drink
지실 및 육계의 복합 추출물 100 mgCombined extract of zyseal and
구연산 1000 ㎎Citric acid 1000 mg
올리고당 100 g100 g of oligosaccharide
매실농축액 2 gPlum concentrate 2 g
타우린 1 gTaurine 1 g
정제수를 가하여 전체 900 ㎖Purified water was added to a total of 900 ml
통상의 건강기능성 음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강기능성 음료 조성물 제조에 사용한다. The above components were mixed according to a conventional health functional beverage manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the resulting solution was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, It is used in the manufacture of the health functional beverage composition of the invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용 용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.
제제예 4. 화장료의 제조Formulation Example 4. Preparation of cosmetic preparation
지실 및 육계의 복합 추출물 100mgCombined extract of flaxseed and broiler 100mg
글리세린 3.0 ㎎3.0 mg of glycerin
하이드로제네이티드 레시친 1.0 ㎎Hydrogenated lecithin 1.0 mg
세토스테아릴알콜 2.0Cetostearyl alcohol 2.0
폴리소르베이트 60 1.5Polysorbate 60 1.5
항산화제 0.3Antioxidant 0.3
방부제 적량Antiseptic
정제수 적량Purified water quantity
Claims (9)
A pharmaceutical composition for preventing or treating allergic dermatitis, which comprises as an active ingredient a complex extract of Poncirus trifoliata and Cinnamommum cassia .
The pharmaceutical composition for preventing or treating allergic dermatitis according to claim 1, wherein the complex extract is extracted with water or an alcohol as an extraction solvent.
The pharmaceutical composition for preventing or treating allergic dermatitis according to claim 1, wherein the combined extract inhibits edema.
The pharmaceutical composition for preventing or treating allergic dermatitis according to claim 1, wherein the allergic dermatitis is contact dermatitis or atopic dermatitis.
A health functional food for prevention or improvement of allergic dermatitis comprising an extract of Zysei and broiler as an active ingredient.
A cosmetic composition for the improvement of allergic dermatitis, which comprises a complex extract of Zysei and broiler as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170059864A KR101821925B1 (en) | 2017-05-15 | 2017-05-15 | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170059864A KR101821925B1 (en) | 2017-05-15 | 2017-05-15 | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130117797A Division KR101738206B1 (en) | 2013-10-02 | 2013-10-02 | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170057213A KR20170057213A (en) | 2017-05-24 |
KR101821925B1 true KR101821925B1 (en) | 2018-01-24 |
Family
ID=59051679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170059864A KR101821925B1 (en) | 2017-05-15 | 2017-05-15 | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101821925B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102213593B1 (en) * | 2019-07-23 | 2021-02-15 | (주)유스케어팜 | Composition for preventing or treating atopic dermatitis comprising extracts of Artemisia capillaris, Cinnamomum cassia, Scutellaria baicalensis and Coptis japonica |
KR102472639B1 (en) * | 2021-02-08 | 2022-11-29 | 한국프라임제약주식회사 | Cosmetic composition for sports massage that has the effect of reducing skin temperature and swelling |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101738206B1 (en) * | 2013-10-02 | 2017-05-22 | 경희대학교 산학협력단 | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis |
-
2017
- 2017-05-15 KR KR1020170059864A patent/KR101821925B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101738206B1 (en) * | 2013-10-02 | 2017-05-22 | 경희대학교 산학협력단 | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis |
Non-Patent Citations (2)
Title |
---|
Journal of Ethnopharmacology. 2011. Vol. 133, pp. 621-628* |
Korean J. Orient. Int. Med. 2000. Vol. 21, No. 1, pp. 156-161* |
Also Published As
Publication number | Publication date |
---|---|
KR20170057213A (en) | 2017-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101498780B1 (en) | Composition for preventing or treating hangover | |
KR102113193B1 (en) | Composition for improving skin conditions comprising artemisiae annuae herba, centella asiatica and green tea extract or fraction thereof and method for improving skin conditions using the same | |
KR20110004603A (en) | Extracts from sophora japonica l. for treating or preventing menopausal complaints, skin-aging, or skin wrinkle | |
KR101874462B1 (en) | Composition for preventing, ameliorating or treating atopic dermatitis comprising Schisandra chinensis leaf extract as effective component | |
KR20150086982A (en) | Composition comprising Polygala tenuifolia extract for preventing or treating atopic dermatitis | |
JP5617110B2 (en) | Oral hair growth promoter | |
KR101671852B1 (en) | Skin whitening composition containing extract or fraction of Euphorbia maculata or Euphorbia supina | |
KR20160144791A (en) | Composition for relieving menopausal symptom | |
KR20220162654A (en) | Composition for protecting eyesight or improving and preventing retinal diseases comprising extracts of stewartia pseudocamellia maxim | |
KR101821925B1 (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
KR20150057333A (en) | Composition comprising extract of korean fir for preventing and improving obesity | |
JP6709783B2 (en) | Composition for preventing hair loss or promoting hair growth containing alpine wormwood extract | |
KR101553378B1 (en) | Composition for Hair Growth Stimulation or Hair Loss Prevention Using Blettia Rhizome Extract, Etc. | |
KR20170109703A (en) | A pharmaceutical composition for preventing or treating cancer comprising fractions of herbal mixture extract | |
KR102371417B1 (en) | Composition for anti inflammation comprising extract of ginseng floral axis | |
KR101919161B1 (en) | Composition for improving condition of hair and preventing hair loss | |
KR101738206B1 (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
KR20160081205A (en) | Composition comprising extract of hydrangea serrata for preventing and improving obesity | |
KR102613550B1 (en) | A ginsenoside complex comprising insoluble substance curcumin | |
KR20170091804A (en) | Composition for treating, improving or preventing allergic disease | |
JP2018506524A (en) | Composition for prevention, amelioration or treatment of burnout syndrome | |
KR102343245B1 (en) | Composition for preventing, ameliorating or treating atopic dermatitis comprising Chrysanthemum indicum L. oil extract as effective component | |
KR100569089B1 (en) | Composition having brain function and congnition enhancing activity | |
KR101700850B1 (en) | Composition for treating, improving or preventing allergic disease containing extract of Triticum aestivum Lamarck | |
KR102101448B1 (en) | Composition for covering body odor comprising extract of korean fir |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |